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Abstract
Background: Cerebral ischemia is usually characterized by a reduction in local blood flow and
metabolism and by disruption of the blood-brain barrier in the infarct region. The formation of
oedema and opening of the blood-brain barrier in stroke is associated with enhanced expression
of metalloproteinase-9 (MMP-9) and tissue inhibitor of metalloproteinase-1 (TIMP-1).
Results: Here, we found an infarct volume of 24.8 ± 2% and a reduced neurological function after
two hours of middle cerebral artery occlusion (MCAO), followed by 48 hours of recirculation in
rat. Immunocytochemistry and confocal microscopy revealed enhanced expression of MMP-9,
TIMP-1, and phosphorylated ERK1/2 in the smooth muscle cells of the ischemic MCA and
associated intracerebral microvessels. The specific MEK1/2 inhibitor U0126, given intraperitoneal
zero or 6 hours after the ischemic event, reduced the infarct volume significantly (11.8 ± 2% and
14.6 ± 3%, respectively; P < 0.05), improved neurological function, normalized expression of
phosphorylated ERK1/2, and reduced expression of MMP-9 and TIMP-1 in the vessel walls.
Administration of U0126 12 hours after MCAO did not alter the expression of MMP-9.
Immunocytochemistry showed no overlap in expression between MMP-9/TIMP-1 and the
astrocyte/glial cell marker GFAP in the vessel walls.
Conclusion: These data are the first to show that the elevated vascular expression of MMP-9 and
TIMP-1, associated with breakdown of the blood-brain barrier following focal ischemia, are
transcriptionally regulated via the MEK/ERK pathway.
Background
Focal cerebral ischemia results from a reduction in cere-
bral blood flow to a discrete region of the brain, initiating
a complex process that includes release of excitatory neu-
rotransmitters and activation of apoptotic pathways. Even
though regional cerebral blood flow is restored to near
normal values after two hours of middle cerebral artery
occlusion (MCAO) followed by reperfusion [1], a cerebral
infarct of about 25% of total brain volume occurs consist-
ently [2]. Some manifestations of the ischemic damage are
break-down of the blood-brain barrier (BBB), activation
of inflammatory cascades, and disruption of basement
membranes and extracellular matrix via cytokine-induced
alterations in the expression of metalloproteinases
(MMPs) and tissue inhibitor of metalloproteinase-1
(TIMP-1) [3]. MMPs are a family of zinc-binding proteo-
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lytic enzymes that can degrade structural proteins of the
extracellular matrix (ECM) and cleave other non-ECM
molecules ranging from growth factor precursors,
cytokines, and binding proteins, to cell surface receptors
[4]. In the central nervous system, MMP-9 is involved in
disruption of the BBB by degrading tight junction proteins
[5]. The proteolytic activity of MMPs is tightly controlled
by tissue inhibitors of MMPs (TIMPs)[6]. By degrading the
neurovascular matrix, MMPs promote BBB injury, causing
brain oedema and haemorrhage. Inhibition of MMP-9
prevents tight junction protein degradation [5], while
excessive expression of MMPs contributes to the patholog-
ical processes. For example, MMP-2 and MMP-9 are
upregulated during cerebral ischemia, however their tem-
poral regulation differs. MMP-9 plays a pivotal role in the
degradation of the BBB after focal cerebral ischemia [7]
and is also expressed in human brain tissue after ischemic
and hemorrhagic stroke [8]. There is an early increase in
MMP-9 expression in the microvascular walls after cere-
bral ischemia and selective inhibition of MMP-9 reduces
the brain injury after stroke [9]. MMP-9 peaks at 48 hours
while MMP-2 peaks at 5 days post stroke. It has been sug-
gested that the balance between MMPs and TIMP-1 plays
a significant role in experimental reperfusion injury [3]
and in human stroke [8,10].
In previous studies, we observed rapid transcriptional
upregulation of contractile endothelin ETB  and angi-
otensin AT1 receptors within the cerebrovascular smooth
muscle cells in the ischemic region in MCAO-induced
focal cerebral ischemia and experimental subarachnoid
haemorrhage [11-13]. It is possible that this upregulation
promotes the formation of the penumbral damage via
enhanced contraction of the vasculature leading to and
within the ischemic region, especially considering that the
receptor ligands (angiotensin II and endothelin-1) are
formed in the cerebrovascular endothelium [14].
Therefore, we examined the early changes in the expres-
sion of MMPs and TIMPs, MMP-9 and TIMP-1 in particu-
lar. This study demonstrates, for the first time, the
enhanced expression of MMP-9 and TIMP-1 after MCAO
followed by reperfusion in cerebrovascular smooth mus-
cle cells. Detailed immunocytochemical analysis revealed
that this enhanced expression was not associated with
other elements of the vessel walls or with glial end-feet or
neurons. We asked whether this enhanced expression was
associated with activation of mitogen-activated protein
kinases (MAPK), a family that includes extracellular sig-
nal-regulated kinases (ERK1/2), p38 MAPK, and c-Jun N-
terminal kinases (JNK), which transmit extracellular sig-
nals into the nucleus to modulate protein expression. Pre-
viously, we observed that ERK1/2 was activated early,
resulting in cerebrovascular receptor upregulation, while
p38 and JNK were activated only after 1–2 days [15,16].
This observation was validated by the results of systemic
administration of the specific MEK1/2 inhibitor U0126
[17], which blunted the enhanced activity of the MEK/
ERK pathway in the cerebrovascular smooth muscle cells.
In addition, we found that MEK1/2 inhibition reduced
the infarct size, improved neurological function, and nor-
malized the enhanced expression of MMP-9 and TIMP-1
that follows ischemic injury.
Results
In this study, we used the rat model of inducible cerebral
ischemia: rats were subjected to reversible MCAO for 2
hours followed by reperfusion for 48 hours [2]. The
MCAO produced an occlusion visible by laser Doppler
flowmetry as an abrupt 80–90% reduction in local corti-
cal blood flow that normalized after removal of the
occluding thread (that was not different from before
occlusion in the operated rats). There were no significant
differences in physiological parameters between the dif-
ferent treatment groups for blood pressure, blood gases,
temperature, plasma glucose, and body weight (data not
shown). Following rapid sacrifice, we collected tissue for
immunocytochemistry, western blot, and calculation of
infarct volume (24.8 ± 2% of total cerebrum in the MCAO
group; Fig. 1A and 1B). Neurological evaluations were
performed just before animal sacrifice (MCAO group, 4.0
± 0.2 versus sham-operated animals with no visible
defects resulting in a score of 0; P < 0.05; Fig. 1C).
Analysis of infarct volume, neurological examination, and 
vessel wall protein expression
Previously, immunocytochemical and western blot analy-
ses showed that MCAO with reperfusion caused activation
of the MEK/ERK pathway in cerebral vessels associated
with the ischemic region [18]; data from our study con-
firm this observation. Firstly, intravenous administration
of the MEK1/2 inhibitor U0126 at 0 or 6 hours after the
two-hour MCAO and initiation of reperfusion signifi-
cantly reduced the infarct volume (11.8. ± 2% and 14.6 ±
3%, respectively; P < 0.05; Fig. 1A and 1B) and improved
neurological assessment scores (2 ± 0.7 and 3.3 ± 0.7,
respectively; P < 0.05; Fig. 1C). When U0126 treatment
was initiated 12 hours after the start of reperfusion, there
was no significant reduction in infarct volume or neuro-
logical score as compared to control animals (21 ± 2%
and 3.8 ± 0.8%, respectively; P < 0.05; Fig. 1). Secondly,
after MCAO, pERK1/2 activity in the vascular smooth
muscle cells was upregulated in large cerebral arteries
(218 ± 11%; P < 0.05) and in microvessels (130 ± 10%; P
< 0.05) but not in adjacent brain tissue (103 ± 4%; P >
0.05), as previously shown [18]. U0126 treatment initi-
ated at zero or 6 hours after initiation of reperfusion nor-
malized vascular pERK1/2 expression (108 ± 5% and 106
± 7%, respectively; P < 0.05).BMC Neuroscience 2009, 10:56 http://www.biomedcentral.com/1471-2202/10/56
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Expression of MMP-1 and TIMP-1
Subsequently, we examined the MCA, cerebral microves-
sels, and the surrounding brain tissue in the ischemic
region and on the contralateral side for changes in expres-
sion of MMP-9 and TIMP-1 protein at 48 hours post
MCAO. We found markedly enhanced expression of
MMP-9 in the vascular smooth muscle cells from the
ischemic region; the expression was localized to the cyto-
plasm, leaving the nuclear regions clear of MMP-9 immu-
noreactivity (Fig. 2A). TIMP-1 expression was observed in
the media layer, but was located closer to the adventitia
layer of the cerebral vessel walls and hence only to some
degree in the smooth muscle cells (Fig. 2A). Quantitative
evaluation of the expression levels revealed significant
upregulation of MMP-9 and TIMP-1 after MCAO in the
MCA and in the microvessels, while only faint staining
was seen in vehicle-treated animals (Table 1, Table 2, Fig.
2B and 2C). Results from double immunostaining for
MMP-9 or TIMP-1, and actin revealed that the expression
of these proteins was localized to the smooth muscle cells
in the MCA and cerebral microvasculature (Fig. 3); how-
ever, their distributions varied slightly (see below). CD31
was used as a marker of endothelial cells; neither MMP-9
nor TIMP-1 revealed any major co-localization with CD31
(data not shown), hence the upregulation occurred in the
media layer. The results from western blot experiments of
MCAs (n = 4 in each group, with 3 animals pooled for
each measurement) showed that the protein levels of
MMP-9 and TIMP-1 were significantly increased after
MCAO as compared to vehicle-treated animals (224 ±
13% and 181 ± 25%, respectively; P  < 0.05; Fig. 4).
Administration of the MEK1/2 inhibitor U0126 immedi-
(A) Following two hours of middle cerebral artery occlusion (MCAO), the area of ischemia in animals treated with U0126 at  zero or 6 hours after the start of reperfusion (b and c, respectively) are smaller than the areas area of ischemia in vehicle- treated animals (a; coronal sections stained with 2, 3, 5-triphenyltetrazolium chloride) Figure 1
(A) Following two hours of middle cerebral artery occlusion (MCAO), the area of ischemia in animals treated 
with U0126 at zero or 6 hours after the start of reperfusion (b and c, respectively) are smaller than the areas 
area of ischemia in vehicle-treated animals (a; coronal sections stained with 2, 3, 5-triphenyltetrazolium chlo-
ride). Treatment with U0126 starting at 12 hours after MCAO (d) did not decrease the area of ischemia. (B) The infarct size 
(% of total brain volume) was significantly decreased in animals treated with U0126 starting at 0 hours (11.8 ± 2%**) and 6 
hours (14.6 ± 3%*) after MCAO as compared to the control group (24.8 ± 2%) and animals treated with U0126 12 hours after 
MCAO (20.3 ± 1%). (C) Neurological assessment scores for U0126-treated rats (0, 6, and 12 hours after MCAO) and vehicle-
treated rats (control). Data are expressed as mean ± SEM; n = 6–7. *P < 0.05, ** P < 0.01.BMC Neuroscience 2009, 10:56 http://www.biomedcentral.com/1471-2202/10/56
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ately after the initiation of reperfusion (0 hour) decreased
the levels of MMP-9 and TIMP-1 proteins by 113 ± 11%
and 126 ± 10%, respectively (Fig. 4).
Association with astrocyte end-feet
GFAP is a selective marker of astrocytes, which are known
to be intimately associated with cerebral microvasculature
[19]. We detected no GFAP-immunopositive end-feet in
the walls of the MCA (or other major cerebral arteries
belonging to the circle of Willis) but confirmed that there
is a rich network of GFAP-positive astrocytes in the cere-
bral cortex tissue (Fig. 5 and 6). Here, the astrocytic end-
feet surrounded the microvasculature, as previously
described[20]. MMP-9 immunoreactions in the MCA and
the microvessels were clearly dissociated from GFAP-pos-
itive staining at all time points studied. However, in the
microvessels (Fig. 5), the astrocytic end-feet closely encir-
cled the vessel walls and came adjacent to the smooth
muscle cells but only in the outermost part of the media
layer, showing a slight merging under confocal micros-
copy. The situation for TIMP-1 was different; TIMP-1
immunoreactivity was mainly present in the outer part of
the media layer and in the adventitia of the cerebral ves-
sels, still closely associated with the smooth muscle cells,
as demonstrated in co-localization studies with actin. In
this part of the vessel walls MMP-9 and TIMP-1 co-located
(data not shown). In microvessels, the association with
astrocytic end-feet was more intimate because both GFAP
(A) Confocal microscopy images of the ischemic middle cerebral artery (MCA), cerebral micro-vessels (Mic.V), and surround- ing brain tissue (Brain) immunofluorescently labeled for MMP-9 (a-f) or TIMP-1 (g-l) Figure 2
(A) Confocal microscopy images of the ischemic middle cerebral artery (MCA), cerebral micro-vessels 
(Mic.V), and surrounding brain tissue (Brain) immunofluorescently labeled for MMP-9 (a-f) or TIMP-1 (g-l). 
Images represent the vehicle control group (a, g), MCAO plus vehicle group (b, h), MCAO plus U0126 starting at 0 hours (c, 
i), 6 hours (d, j), or 12 hours (e, k) groups, and the negative control group (f, l). There was a significant increase in the MMP-9 
protein level in the smooth muscle cell layer of ischemic vessels (MCA and Mic.V) as compared with vessels from the vehicle 
control group. TIMP-1 expression was upregulated in smooth muscle cells and in the proximity of the adventitia layer of 
ischemic vessels as compared to control vessels. Treatment with U0126, starting at zero and 6 hours, but not at 12 hours, 
after occlusion prevented the increase in MMP-9 and TIMP-1 protein expression. There was a slight increase in MMP-9 protein 
expression in ischemic brain tissue and in astrocytes around the vessels as compared to control and U0126-treated brain tis-
sue. For TIMP-1, was no difference in protein expression in control brain tissue, in ischemic brain tissue, or tissue from animals 
treated with U0126. Scale bar, 50 μm. (B, C) Bar graphs showing the fluorescence intensity for MMP-9 and TIMP-1 in the 
MCA and micro-vessels. There was a significant increase in MMP-9 and TIMP-1 protein expression in MCAO animals as com-
pared to control animals; this increase was prevented with U0126 treatment starting at zero and 6 hours, but not 12 hours, 
post MCA. Data are presented as the mean percentage relative to control ± SEM.; n = 5. *P < 0.05, **P < 0.01.BMC Neuroscience 2009, 10:56 http://www.biomedcentral.com/1471-2202/10/56
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and TIMP-1 immunoreactivity occurred in the outermost
part of the media and in the adventitia, sometimes
appearing merged in the walls of the microvessels (Fig. 6).
Inhibition of MEK1/2 activity in vivo
Next, we assessed whether the MEK/ERK pathway was
activated in the walls of the MCA, the microvessels, and
surrounding brain tissue following MCAO. Results from
immunostaining with pERK1/2-specific antibodies
showed that pERK1/2 expression in the smooth muscle
cells in the vasculature was significantly increased in the
ischemic region at 48 hours post MCAO (174 ± 6%; P <
0.05). Systemic administration of the MEK1/2-specific
inhibitor U0126 [21] either immediately after release of
the occlusion (0 hour) or 6 hours post MCAO recircula-
tion effectively abolished the increase in pERK1/2 activity
in the ischemic MCA and the cerebral microvessels (see
above). However, there was no visible alteration in
pERK1/2 activity in brain tissue of the ischemic (117 ±
13%; P > 0.05) or contralateral regions (data not shown).
Treatment with U0126 (beginning at 0 and 6 hours post
MCAO) significantly decreased the upregulation of MMP-
9 and TIMP-1 in both the MCA and the cerebral microves-
sels within the infarct area (Table 1 and 2) but no differ-
ence in brain tissue per se (Table 3). However,
administration of U0126 beginning 12 hours after reper-
fusion did not significantly reduce the ischemia-induced
expression of MMP-9 or TIMP-1 in the cerebral vessel
smooth muscle cells (Table 1 and 2). These results were
confirmed at the protein level by western blot.
Discussion
This is the first study to clearly demonstrate that two-hour
MCAO followed by 48 hours of reperfusion results in sig-
nificant upregulation of MMP-9 and TIMP-1 in the
smooth muscle cells of the MCA and in microvessels
within the ischemic region. Furthermore, our data show
that this upregulation is associated with upregulation of
pERK1/2 and normalized by inhibition of the MEK/ERK
pathway.
To determine the cellular source of MMP-9 and TIMP-1,
we performed confocal microscopy and co-localization
studies using smooth muscle actin-specific antibodies.
MMP-9 immunoreactivity was localized to the cytoplasm
Double immunofluorescence staining for MMP-9 or TIMP-1 and actin in smooth muscle cells of the middle cerebral artery after  MCAO Figure 3
Double immunofluorescence staining for MMP-9 or TIMP-1 and actin in smooth muscle cells of the middle cer-
ebral artery after MCAO. (A-C) Photographs demonstrating the localization of MMP-9, actin immunostaining, and their co-
localization in smooth muscle cells (yellow fluorescence in the merged picture). (D-F) TIMP-1 immunostaining, actin immunos-
taining, and their co-localization in the smooth muscle cells (white arrows). Scale bar, 50 μm.BMC Neuroscience 2009, 10:56 http://www.biomedcentral.com/1471-2202/10/56
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of the cerebral vessel smooth muscle cells, both in the
MCA and in intracerebral microvessels. Although minor
amounts of actin has been observed in endothelial cells
we could easily dissociate microscopically the endothe-
lium from the smooth muscle cells as they are separated
by an inner elastic lamina [22]. In addition, some vessels
were studied after mechanical removal of the endothe-
lium. After this procedure the localization of the immuno-
reactions to the smooth muscle cells was still confirmed
(data not shown). This increase in immunoreactivity
agrees with a previously reported increase in MMP-9
mRNA and protein expression in the ischemic tissue at 24
hours after MCAO (without any change in MMP-2
mRNA), and this correlated with opening of the BBB [5].
These investigators observed that MMP-2 co-localized
with GFAP-expressing astrocytes and with neurons in the
lateral and piriform cortices, but not in the vessel walls
[5]. It was also shown that increased MMP-9 activity was
associated with a reduction in junction proteins in cere-
brovascular endothelial cells and in BBB disruption after
focal ischemia [23]. Detailed analysis revealed that these
events were caused by MMP-9-mediated degradation of
the junction proteins claudin-5 and occludin. In support
of these data, the administration of an MMP-9 blocker
prevented this degradation and abolished the BBB dam-
age [5].
There exist some data on the time-dependency of the ele-
vation in expression of MMP-9 in the cerebral vessel walls.
Thus, the direct comparison of MMP-9 expression in the
present ischemic model with that seen in experimental
subarachnoid haemorrhage (SAH) and after organ culture
of isolated MCA segments revealed enhanced levels of
MMP-9 mRNA at 6 and 24 hrs [24]. The time-course was
studied in more detail after experimental SAH; the main
expression of MMP-9 was seen at 48 hours [25].
The specific MEK1 inhibitor U0126 does not affect phos-
phorylation of p38 or JNK in cultured neurons [17] or in
cerebrovascular smooth muscle cells in vivo using the
Immunoblots showing MMP-9 and TIMP-1 protein expression levels in the middle cerebral artery 48 hours after MCAO using  β-actin as a loading control Figure 4
Immunoblots showing MMP-9 and TIMP-1 protein expression levels in the middle cerebral artery 48 hours 
after MCAO using β-actin as a loading control. Treatment with U0126 at 0 hours post occlusion decreased the MCAO-
induced enhanced expression of MMP-9 and TIMP-1 receptor proteins. Data from four experiments (each performed on ves-
sels from 3 rats) are expressed as mean ± SEM, n = 4. *P < 0.05, **P < 0.01.
Table 1: Levels of MMP-9 and TIMP-1 protein in the middle cerebral artery after MCAO and after treatment with the MEK1/2 
inhibitor U0126 at 0, 6, and 12 hours post occlusion
Middle cerebral artery
Control MCAO MCAO + U0126 - 0 h MCAO + U0126 - 6 h MCAO + U0126 - 12 h
MMP-9 (%) ± SEM 100 ± 3 198 ± 7** 114 ± 10§ 113 ± 8§ 144 ± 5
TIMP-1 (%) ± SEM 100 ± 5 191 ± 7** 137 ± 5 100 ± 4§§ 184 ± 19BMC Neuroscience 2009, 10:56 http://www.biomedcentral.com/1471-2202/10/56
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present model of ischemia [24]. Detailed western blot
experiments have confirmed the specificity of U0126 on
the MEK/ERK pathway [26]. Therefore, we can rule out
that U0126 acts via non-specific inhibition of the pro-
apoptotic and pro-inflammatory mechanisms since
unknown non-MEK effects cannot be ruled out. U0126
has been found to increase MEK1/2 phosphorylation in
cortical neurons, thus U0126 does not affect components
upstream of MEK1/2 [27]. Hence, it is reasonable to
assume that the neuroprotective effect of U0126 results
from the inhibition of cerebrovascular MEK1/2 activity,
which agrees with the observed reductions in the activity
of the downstream MAPK, pERK1/2. In this study, we
showed that MCAO resulted in enhanced expression of
pERK1/2 in smooth muscle cells of the ischemic MCA and
associated microvessels (shown by co-localization with
actin) but not in the surrounding brain tissue; U0126
blunted this activation, reduced the infarct volume, and
improved the neurological assessment scores of treated
rats. Intriguingly, inhibiting this sequence of events corre-
lated with the inhibition of MMP-9 and TIMP-1 expres-
sion in the same location. Quantitative real time-PCR
Table 2: Levels of MMP-9 and TIMP-1 protein in the microvessels after MCAO and after treatment with U0126 at 0, 6, and 12 hours 
post occlusion
Cerebral microvessels
Control MCAO MCAO + U0126 - 0 h MCAO + U0126 - 6 h MCAO + U0126 - 12 h
MMP-9 (%) ± SEM 100 ± 3.5 127 ± 1.5* 90 ± 9.8§ 92.5 ± 4.05§ 97 ± 4.4
TIMP-1 (%) ± SEM 100 ± 5 141 ± 2.6* 104 ± 5.3§ 101 ± 6§ 129 ± 7.3
Double immunofluorescence staining for MMP-9 and GFAP demonstrate their localization in the middle cerebral artery  (MCA), microvessels, and in surrounding brain tissue Figure 5
Double immunofluorescence staining for MMP-9 and GFAP demonstrate their localization in the middle cere-
bral artery (MCA), microvessels, and in surrounding brain tissue. MMP-9 expression in the smooth muscle cells of the 
MCA, micro-vessels, and brain tissue after MCAO is shown in (A) and (D) (pink arrows). GFAP expression was observed in 
astrocytes around the MCA, microvessels, and in the brain tissue (B and E). The merged images show the co-localization of 
MMP-9 and GFAP (C and F). There was no co-localization between MMP-9 and GFAP in the MCA (C), but there was some 
co-localization between MMP-9 and GFAP in the brain tissue and modest co-localization in the astrocytic end-feet surrounding 
the microvessels (white arrows).BMC Neuroscience 2009, 10:56 http://www.biomedcentral.com/1471-2202/10/56
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demonstrated enhanced mRNA expression of MMP-9 24
hours after MCAO in cerebral blood vessels in focal
ischemia, and at 24 and 48 hours after experimental SAH
[24]. Our data indicate, for the first time, that the expres-
sion of MMP-9 and TIMP-1 in cerebral blood vessel
smooth muscle cells is enhanced after cerebral ischemia
and that this enhancement is a transcriptional event.
While constitutively expressed MMP-2 is involved in an
early brief loosening of tight junctions and the initial
reversible opening of the BBB, MMP-9 expression
increases with time, is more durable, and is possibly
related to increased neuroinflammation [5]. Importantly,
the opening of the BBB is associated with brain damage
and our observations reveal a mechanism by which to
modify the expression of MMP-9, thereby reducing the
risk of brain damage: inhibiting MEK1/2.
Although MEK/ERK-pathway mechanisms play a crucial
roles in mediating brain injury after ischemia and reper-
fusion, and inhibiting this pathway can reduce the infarct
size [17,28], we provide direct evidence supporting an
explanation for some of the events related to the focal
pathology of cerebral ischemia [29]. U0126 administra-
tion diminished pERK1/2 immunoreactivity in the
Double immunofluorescence staining for TIMP-1 and GFAP show their localization in the MCA, microvessels, and brain tissue Figure 6
Double immunofluorescence staining for TIMP-1 and GFAP show their localization in the MCA, microvessels, 
and brain tissue. TIMP-1 expression was seen in the cell walls of the MCA and microvessels and in nerve cells and astrocytes 
in the brain tissue (pink arrows; A, D, and G). GFAP expression was observed in the astrocyte cells around the MCA and 
microvessels and in the brain tissue (B, E, and H). Illustration of the co-localization of TIMP-1 and GFAP expression (C, F, and 
I). TIMP-1 immunoreactivity co-localized with GFAP immunoreactivity in the nerve cells and some areas of astrocytes in the 
brain tissue (C) and at the outer layer of microvessels; these areas were surrounded by astrocytic end-feet (white arrows; F 
and I).BMC Neuroscience 2009, 10:56 http://www.biomedcentral.com/1471-2202/10/56
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ischemic brain of the mouse [17] and in the MCA of the
rat [28]. In the mouse model, three hours of MCAO was
followed by 24 hours of reperfusion. Interestingly, the inf-
arct volume was affected only if U0126 was given in con-
junction with the MCAO [17]. Furthermore, in a
permanent MCAO model, pre-treatment with U0126 was
necessary to inhibit pMEK1/2/pERK1/2 expression in vivo
in the mouse brain in both the ischemic core and perifocal
regions [30]. Also, the specificity of the antagonism
revealed that U0126 does not inhibit the cellular synthesis
of ERK1/2 but does block the ERK1/2 phosphorylation
and activation of, for example, the transcription factor
ELK-1 [30,31]. In agreement with our observations,
MEK1/2 inhibition does not alter cortical blood flow
within the first few hours of administration [17,32] or
modify the contractility of isolated cerebral arteries
(unpublished data). Hence, U0126 does not act on the
cerebral circulation through a direct vasodilator mecha-
nism. Instead, we suggest that U0126 blunts receptor
upregulation [28].
Here, we have demonstrated yet another positive effect of
U0126: blocking the enhanced expression of MMP-9,
which participates in the destruction of the BBB and sub-
sequent brain oedema. More importantly, systemic
administration of U0126 markedly reduced the infarct
size and improved neurological function, even when the
first dose was given as late as 6 hours after the initiation of
reperfusion. Clearly, these data differ to some degree from
those found in previous reports. While U0126 is a well-
known inhibitor of MEK1/2, it has a questionable perme-
ability of the BBB. In order to overcome this hurdle, we
used a much higher dosage of U0126 (30 mg/kg) than
that used by others, which still did not alter any physio-
logical parameters and was well tolerated by the rats. This
dosage is much higher than that necessary to inhibit the
MEK/ERK pathway in cell culture but is necessary to allow
a sufficient dosage to reach the abluminal side of the BBB;
this was verified by protein expression using both immu-
nohistochemistry and western blot. We verified the suc-
cess of the antagonism by demonstrating that MCA and
cerebral microvascular pERK1/2 activities were reduced to
control levels and this reduction was associated with a sig-
nificant reduction in infarct size and reduced expression
of MMP-9 and TIMP-1. If U0126 treatment was initiated
12 hours after the start of reperfusion, there was no signif-
icant effect on the above parameters. Therefore, at this
dosage, the MEK1 inhibitor U0126 may have a therapeu-
tic window.
Conclusion
We hypothesise that MEK/ERK inhibition might represent
a way to prevent stroke-induced pathology because it tar-
gets several transcriptional mechanisms activated by cere-
bral ischemia, such as receptor upregulation, which causes
enhanced contractility, and MMP-9 and TIMP1 activation,
which affect the function of the BBB. Inhibition of the
MEK/ERK pathway applied as late as 6 hours after the start
of reperfusion significantly reduced the infarct volume
and the expression of BBB-associated proteins MMP-9 and
TIMP1 in the cerebral vessel walls. Thus, the positive
effects of MEK/ERK inhibition might involve several
mechanisms in the MCA and in brain microvasculature
associated with the cerebral ischemia. However, the dos-
age required to reach targets on the abluminal side of the
BBB is a factor that warrants further study.
Methods
Middle cerebral artery occlusion
A total of 56 Male Wistar-Hanover rats (Møllegaard Breed-
ing Centre, Copenhagen, Denmark) weighing approxi-
mately 300–350 g were obtained from Harlan, Horst,
Netherlands, and were used for the procedures. The ani-
mals were housed under controlled temperature and
humidity with free access to water and food. The experi-
mental procedures were approved by the University Ani-
mal Ethics Committee (M43-07).
Anaesthesia was induced using 4.5% halothane in
N2O:O2 (70%:30%) and was maintained by inhalation of
1.5% halothane by mask. To confirm proper occlusion of
the right MCA, a laser-Doppler probe (Perimed, Järfälla,
Sweden) was fixed on the skull (1 mm posterior to the
bregma and 6 mm from the midline on the right side) to
Table 3: Levels of MMP-9 and TIMP-1 protein in brain tissue after MCAO and after treatment with U0126 at 0, 6, and 12 hours post 
occlusion
Brain tissue
Control MCAO MCAO + U0126 - 0 h MCAO + U0126 - 6 h MCAO + U0126 - 12 h
MMP-9 (%) ± SEM 100 ± 5.8 125 ± 8.0 101 ± 6.5 102 ± 4.7 109 ± 7.2
TIMP-1 (%) ± SEM 100 ± 3.8 113 ± 2.7 111 ± 5 105 ± 2.7 112 ± 5.2
Values are percentages of the control value and are reported as mean ± standard error of the mean (SEM); n = 5–6, *P < 0.05, **P < 0.01, §P < 0.05, 
§§ P < 0.01. *Indicates a significant difference between the control group and the MCAO group; § indicates a significant difference between the 
MCAO group and the U0126-treated group.BMC Neuroscience 2009, 10:56 http://www.biomedcentral.com/1471-2202/10/56
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measure local cortical blood flow in an area supplied by
the MCA. A polyethylene catheter was inserted into a tail
artery to measure the mean arterial blood pressure, pH,
pO2, pCO2, and plasma glucose. A rectal temperature
probe connected to a homeothermal blanket was used to
maintain body temperature at 37°C during the procedure.
An intraluminal filament technique was used to induce
transient MCAO [2]. Briefly, an incision was made in the
midline of the neck and the right common, external, and
internal carotid arteries were exposed. The common and
external carotid arteries were permanently ligated with
sutures. A filament was inserted into the internal carotid
artery via an incision in the common carotid artery and
advanced until the rounded tip reached the entrance to
the right MCA. The resulting occlusion was visualized by
laser-Doppler as an abrupt 80–90% reduction in local cor-
tical blood flow After 2 h of occlusion, the rat was re-anes-
thetized to allow withdrawal of the filament; reperfusion
was verified by laser-Doppler recording. 20–30% of the
animals were terminated in conjunction with surgery and
MCAO due to imperfect drop in laser-Doppler flow. (They
were not included because they did not show the expected
reduction in blood flow).
Treatments
To inhibit MEK1/2, animals were injected intraperitoneal
with 30 mg/kg/day of U0126 dissolved in dimethylsulfox-
ide (DMSO), beginning at reperfusion (0 h), at 6 h, 12 h,
or 24 h post occlusion [33]. Rats in the control groups
were injected with equal volumes of DMSO. The dose of
U0126 was chosen on the basis of previous experiments
[18].
Harvesting cerebral vessels and brain tissue
At 48 h post MCA occlusion, MCAO rats, and MCAO rats
treated with U0126, and their respective DMSO controls
were anesthetized and decapitated. The brains were
removed and immersed in ice-cold bicarbonate buffer
solution of the following composition (mM): NaCl 119,
NaHCO3, 15, KCl 4.6, MgCl2 1.2, NaH2PO4 1.2, CaCl2
1.5, and glucose 5.5. The right and left MCAs and sur-
rounding brain tissue were dissected out using a dissec-
tion microscope, snap frozen, and stored at -80°C for
immunohistochemical analysis. A large number of proxi-
mal MCA segments were also harvested and pooled for
protein extraction and western blot analysis.
Neurological examination
The animals were subjected to a neurological examination
prior to recirculation and immediately before they were
sacrificed (48 hours after MCAO), according to an estab-
lished scoring system [34,35]: 0, no visible deficit; 1, con-
tralateral forelimb flexion, when held by tail; 2, decreased
grip of contralateral forelimb; 3, spontaneous movement
in all directions, but contralateral circling if pulled by tail;
4, spontaneous contralateral circling; 5, death.
Brain damage evaluation
The brains were sliced coronal in 2-mm thick slices and
stained with 0.5 mg/ml 1% 2, 3, 5-triphenyltetrazolium
chloride (Sigma, St Louis, MO) dissolved in buffer solu-
tion at 37°C for 20 minutes. The extent of the ischemic
brain damage was calculated as a percentage of the total
brain volume in the slices using the software program
Brain Damage Calculator 1.1 (MB Teknikkonsult, Lund,
Sweden). The pictures were evaluated by two independent
researchers unknown to the treatment group.
Immunofluorescence
For immunofluorescence analysis, the MCA and the sur-
rounding brain tissue were dissected out, placed into Tis-
sue TEK (Gibo, Invitrogen A/S, Taastrup, Denmark), and
frozen on dry ice; thereafter, they were sectioned into 10-
μm thick slices. Cryostat sections of the arteries and brain
tissue were fixed for 10 minutes in ice-cold acetone (-
20°C) and then rehydrated in phosphate buffer solution
(PBS) containing 0.3% Triton X-100 for 15 minutes. The
tissues were then permeabilized and blocked for 1 hour in
blocking solution containing PBS, 0.3% TritonX-100, 1%
bovine serum albumin (BSA), and 5% normal donkey
serum, and then incubated over night at 4°C with either
rabbit anti-phosphoERK1/2 MAPK (ab4376; Cellsignal-
ing, Danvers, MA) diluted 1:50, rabbit anti-rat MMP-9
(ab7299; Abcam, Cambridge, MA) diluted 1:400, or rab-
bit anti-human TIMP-1 (AB770; Chemicon, Copenhagen,
Denmark) diluted 1:200. All primary antibodies were
diluted in PBS containing 0.3% Triton X-100, 1% BSA,
and 2% normal donkey serum. Sections were subse-
quently incubated for 1 hour at room-temperature with
secondary Cy™2-conjugated donkey anti-rabbit (711-165-
152; Jackson ImmunoResearch, Europe Ltd., Suffolk, UK)
diluted 1:200 in PBS containing 0.3% Triton X-100 and
1% BSA. The sections were subsequently washed with PBS
and mounted with Permafluore mounting medium
(Beckman Coulter, PNJM0752). Immunoreactivity was
visualized and photographed using a Nikon confocal
microscope (EZ-c1, German) at the appropriate wave-
length. The same procedure was used for the negative con-
trols except that primary or secondary antibodies were
omitted. There was also a know sample as positive control
to compare with the present samples to avoided any prob-
ability failure in results. Data using blocking peptide
(sequence used for the immunization) were provided by
the supplier.
Double immunofluorescence
Double immunofluorescence labelling was performed for
TIMP-1, MMP-9, and phosphorylated ERK1/2 versus
smooth muscle actin or glial fibrillary acidic proteinBMC Neuroscience 2009, 10:56 http://www.biomedcentral.com/1471-2202/10/56
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(GFAP), an astrocyte/glial cell marker. In addition to the
antibodies described above, we used mouse anti-rat
smooth muscle actin antibodies (SC-53015; Santa Cruz
Biotechnology, Inc, Santa Cruz, CA) diluted 1:200 and
mouse anti-GFAP (G3893; Sigma) diluted 1:600 in PBS
containing 0.3% Triton X-100, 1% BSA, and 2% normal
donkey serum. The secondary antibodies were Cy™2-con-
jugated donkey anti-rabbit (Jackson ImmunoResearch)
diluted 1:200 and Texas Red-labeled donkey anti-mouse
(Jackson ImmunoResearch Europe) diluted 1:300 in PBS
containing 3% Triton X-100 and 1% BSA. The antibodies
were detected at the appropriate wavelengths using a con-
focal microscope (EZ-cl, Germany).
Image analysis
Fluorescence intensity was measured using ImageJ soft-
ware http://rsb.info.nih.gov/ij/. Measurements were
made in 4 different preset areas (located on the clock at 0,
3, 6 and 9 h) from 4 vessel sections from each vessel sam-
ple and the investigator was blinded to the treatment
group of each sample. The fluorescence intensity of each
treatment group was given as the percentage change rela-
tive to control; the control value was normalized to 100%.
The mean value for each was used for comparisons
[33,36].
Western blotting
Proximal MCA segments (n = 12 rats in each group; ves-
sels from 3 rats were pooled for each measurement and
experiments were done in total 4 times) were harvested
and frozen in liquid nitrogen and homogenized in cell
extract denaturing buffer (BioSource, Carlsbad, CA) that
contained both phosphatase inhibitor and protease
inhibitor cocktails (Sigma). Whole cell lysates were soni-
cated on ice for 2 min, centrifuged at 15 000 × g at 4°C for
30 min, and the supernatants were collected as protein
samples. Protein concentrations were determined using
standard protein assay reagents (Bio-Rad, Hercules, CA)
and stored at -80°C awaiting immunoblot analysis. The
protein homogenates were diluted 1:1 (v/v) with 2×
sodium dodecyl sulfate (SDS) sample buffer (Bio-Rad).
Protein samples (25–50 μg of total protein) were boiled
for 10 min in SDS sample buffer and separated on 4–15%
SDS Ready Gel Precast Gels (Bio-Rad, USA) for 120 min at
100 v and transferred to nitrocellulose membranes by
electroblotting (Bio-Rad) at 100 v for 60 min. The mem-
brane was then blocked for 1 hour at room temperature
with PBS containing 0.1% Tween-20 (Sigma) and 5%
non-fat dried milk and incubated with primary antibod-
ies, as appropriate [rabbit anti-rat MMP-9 (ab7299;
Abcam) and rabbit anti-human TIMP-1 (AB770; Chemi-
con)], diluted 1:200-1 000 overnight at 4°C, followed by
incubation with horseradish peroxidase (HRP)-conju-
gated anti-rabbit IgG secondary antibodies (Amersham
Biosciences, Piscataway, NJ) diluted 1: 5 000–10 000 for
1 hour at room temperature. The labeled proteins were
developed using the LumiSensor Chemiluminescent HRP
Substrate kit (GenScript Corp., Piscataway, NJ). To detect
multiple signals on a single membrane, the membrane
was incubated in Restore Plus western blot stripping
buffer for 5–15 min at room temperature (Pierce Biotech-
nology, Inc., Rockford, IL) between the various labeling
procedures. The membranes were visualized using a Fuji-
film LAS-1000 Luminescent Image Analyzer (Stamford,
CT), and band intensity was quantified using Image
Gauge Version 4.0 (Fuji Photo Film Co., Ltd., Japan).
Three independent experiments were performed in dupli-
cate.
Calculations and statistical analyses
Data are expressed as the mean ± standard error of the
mean (SEM). Statistical analyses were performed using
the nonparametric Kruskal-Wallis test with Dunn's post
hoc test for quantitative immunohistochemistry and west-
ern blot evaluation. One-way analysis of variance
(ANOVA) with Dunnett's test was used for infarct volume
studies (using GraphPad Prism v 4). P-values less than
0.05 were considered significant; "n" refers to the number
of rats.
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